Oncology drugs extending median survival by 4-9 weeks or 9 days while costing $40,000-$100,000+ are approved and marketed, illustrating industry incentive to focus on median rather than overall survival.
factualpending
Speaker
Peter AttiaEvidence Quote
“drugs that are extending median Survival by four weeks are being put on the market at a tune of you know $50 to $100,000 per treatment... there was one drug that was approved for pancreatic cancer... it extended median Survival by nine days and it cost $40,000”
Source
286‒Journal club with Andrew Huberman: light exposure on mental health & an immunotherapy for cancer— Peter Attia MDCreated: 8/11/2026, 1:49:16 AM
My Notes
Loading notes...